Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

Our study suggests that the discontinuation of FDC treatment and the replacement with the administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs. </AbstractSection> Copyright Homar et al.; licensee Springer. 2012

MoreLess

Year of publication:	2012
Authors:	Homar, Francesc ; Lozano, Virginia ; Martínez-Gómez, Juan ; Oyagüez, Itziar ; Pareja, Antonio ; Payeras, Antoni ; Serrano, Joaquín ; Carratalá, Carmen ; Casado, Miguel
Published in:	Health Economics Review. - Springer. - Vol. 2.2012, 1, p. 1-9
Publisher:	Springer
Subject:	HIV \| Fixed-dose combination \| Antiretrovirals \| Cost-analysis \| Spain

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10010998789